In patients with macular edema resulting from RVO , there was no short-term clinically significant benefit from monthly injections of 2.0-mg versus 0.5-mg ranibizumab injections and no long-term benefit in BCVA , resolution of edema , or number of ranibizumab injections obtained by addition of laser treatment to ranibizumab .